FLGT

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

Wall Street analysts forecast FLGT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FLGT is 32.50 USD with a low forecast of 30.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Fulgent Genetics Inc revenue for the last quarter amounts to 84.07M USD, increased 17.18 % YoY.

Fulgent Genetics Inc. EPS for the last quarter amounts to -0.21 USD, decreased -56.25 % YoY.

Fulgent Genetics Inc (FLGT) has 1313 emplpoyees as of December 17 2025.

Today FLGT has the market capitalization of 839.58M USD.